Goldman Sachs Sets Neutral Stance on China Life with HK$28.5 Price Objective

Deep News06-21

Goldman Sachs has issued a research report assigning a Neutral rating to China Life Insurance Company Limited (HKG: 2628). The firm established a 12-month target price of HK$28.5, derived from a 1.0x expected price-to-book ratio projected for 2027 and based on return on total assets. Key investor inquiries have centered on the sales outlook, the potential for growth and disruptions within bancassurance channels, as well as investment and dividend matters.

The insurer has reaffirmed its target of achieving double-digit new business value growth by 2026 and has emphasized its competitive edge in the bancassurance distribution network. A robust performance in the equity market during the second quarter of 2026 has already contributed to an improvement in investment results.

For investors concerned about base effects in the third quarter, the company suggested focusing on full-year profitability, particularly given the lower comparative base expected in the fourth quarter. Management has also expressed a commitment to working towards reducing the volatility in the dividend per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment